

Market Applicability				
Market	GA	MD	NJ	NY
Applicable	X	X	X	X

Cinqair (reslizumab) Fasenra (benralizumab) Nucala (mepolizumab)

Override(s)	Approval Duration
Prior Authorization	Initial requests: 6 months
Quantity Limit	Continuation requests: 1 year

Medications	Quantity Limit	Dosing Limit
Cinqair (reslizumab) 100 mg vial		3 mg/kg every 4 weeks
Fasenra (benralizumab) 30 mg/ml prefilled syringe/autoinjector	30 mg (1 syringe/autoinjector) every 8 weeks	
Nucala (mepolizumab) 100 mg vial, 100 mg/ml prefilled syringe/autoinjector	100 mg (1 vial/syringe/autoinjector) every 4 weeks	

For Fasenra, may approve 1 additional 30 mg prefilled syringe/autoinjector at week 4. The total allowed quantity for initiation of therapy is 30 mg once every 4 weeks for the first 3 doses.

For Nucala, may approve up to 300 mg every 4 weeks if individual is using for eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome (HES).

APPROVAL CRITERIA

Initial requests for Cinqair (reslizumab) may be approved for severe **eosinophilic asthma** when the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual has a diagnosis of severe eosinophilic asthma; **AND**
- III. Evidence of asthma is demonstrated by the following (NAEPP, 2008):
 - A. A pretreatment forced expiratory volume in 1 second (FEV₁) less than 80% predicted; **AND**
 - B. FEV₁ reversibility of at least 12% and 200 ml after albuterol administration;
- AND**
- IV. Documentation is provided that individual has had a 3 month trial and inadequate response or intolerance to combination controller therapy (high dose inhaled

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability				
Market	GA	MD	NJ	NY
Applicable	X	X	X	X

corticosteroids plus long acting beta₂ –agonists, leukotriene modifiers, long-acting muscarinic antagonists or oral corticosteroids) (ERS/ATS, 2013; GINA 2020); **AND**

- V. Individual has experienced two or more asthma exacerbations in the prior 12 months requiring use of a systemic corticosteroid or temporary increase in the individual's usual maintenance dosage of oral corticosteroids (ERS/ATS, 2013); **AND**
- VI. Documentation is provided that individual has blood eosinophil count (in the absence of other potential causes of eosinophilia, including hypereosinophilic syndromes, neoplastic disease, and known or suspected parasitic infection) greater than or equal to 400 cells/microliter (400 cells/mm³) at initiation of therapy.

Initial requests for Fasenra (benralizumab) for severe **eosinophilic asthma** may be approved if the following criteria are met:

- I. Individual is 12 years of age or older; **AND**
- II. Individual has a diagnosis of severe eosinophilic asthma; **AND**
- III. Evidence of asthma is demonstrated by the following (NAEPP, 2008):
 - A. A pretreatment forced expiratory volume in 1 second (FEV₁) less than 80% predicted; **AND**
 - B. FEV₁ reversibility of at least 12% and 200 milliliters (ml) after albuterol administration;

AND

- IV. Documentation is provided that individual has had a 3 month trial and inadequate response or intolerance to combination controller therapy (high dose inhaled corticosteroids plus long acting beta₂ –agonists, leukotriene modifiers, long acting muscarinic antagonists or oral corticosteroids) (ERS/ATS, 2013; GINA 2020);

AND

- V. Individual has experienced two or more asthma exacerbations in the prior 12 months requiring use of a systemic corticosteroid or temporary increase in the individual's usual maintenance dosage of oral corticosteroids (ERS/ATS, 2013);

AND

- VI. Documentation is provided that individual has a blood eosinophil count (in the absence of other potential causes of eosinophilia, including hypereosinophilic syndromes, neoplastic disease, and known or suspected parasitic infection) greater than or equal to 300 cells/microliter (300 cells/mm³) at initiation of therapy.

Initial requests for Nucala (mepolizumab) for severe **eosinophilic asthma** may be approved if the following criteria are met:

- I. Individual is 6 years of age or older; **AND**

PAGE 2 of 6 08/01/2021

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability				
Market	GA	MD	NJ	NY
Applicable	X	X	X	X

- II. Individual has a diagnosis of severe eosinophilic asthma; **AND**
- III. Evidence of asthma is demonstrated by the following (NAEPP, 2008):
 - A. A pretreatment forced expiratory volume in 1 second (FEV₁) less than 80% predicted; **AND**
 - B. FEV₁ reversibility of at least 12% and 200 milliliters (ml) after albuterol administration;
- AND**
- IV. Documentation is provided that individual has had a 3 month trial and inadequate response or intolerance to combination controller therapy (high dose inhaled corticosteroids plus long acting beta₂ –agonists, leukotriene modifiers, long-acting muscarinic antagonists or oral corticosteroids) (ERS/ATS, 2013; GINA 2020); **AND**
- V. Individual has experienced two or more asthma exacerbations in the prior 12 months requiring use of a systemic corticosteroid or temporary increase in the individual's usual maintenance dosage of oral corticosteroids (ERS/ATS, 2013); **AND**
- VI. Documentation is provided that individual has one of the following blood eosinophil counts (in the absence of other potential causes of eosinophilia, including hypereosinophilic syndromes, neoplastic disease, and known or suspected parasitic infection):
 - A. Greater than or equal to 150 cells/microliter (150 cells/mm³) at initiation of therapy; **OR**
 - B. Greater than or equal to 300 cells/microliter (300 cells/mm³) in the prior 12 months.

Continuation requests for Cinqair (reslizumab), Fasenra (benralizumab), or Nucala (mepolizumab) for severe **eosinophilic asthma** may be approved if the following criteria are met:

- I. Treatment with Cinqair (reslizumab), Fasenra (benralizumab), or Nucala (mepolizumab) has resulted in clinical improvement as confirmed by one or more of the following:
 - A. Decreased utilization of rescue medications; **OR**
 - B. Decreased frequency of exacerbations (defined as worsening of asthma that requires an increase in inhaled corticosteroid dose or treatment with systemic corticosteroids); **OR**
 - C. Increase in percent predicted FEV₁ from pretreatment baseline; **OR**
 - D. Reduction in reported asthma-related symptoms, such as, asthmatic symptoms upon awakening, coughing, fatigue, shortness of breath, sleep disturbance, or wheezing.

Initial requests for Nucala (mepolizumab) for **eosinophilic granulomatosis with polyangiitis** when the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual has been diagnosed with relapsing or refractory eosinophilic granulomatosis with polyangiitis for 6 months defined as (Wechsler, 2017):

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability				
Market	GA	MD	NJ	NY
Applicable	X	X	X	X

- A. A history or presence of asthma; **AND**
- B. A blood eosinophil level of greater than or equal to 10% of leucocytes or an absolute eosinophil count of greater than 1000 cells per mm³ (in the absence of other potential causes of eosinophilia, including hypereosinophilic syndromes, neoplastic disease, and known or suspected parasitic infection), and documentation is provided; **AND**
- C. The presence of two or more features of eosinophilic granulomatosis with polyangiitis (such as, a biopsy showing histopathological evidence of eosinophilic vasculitis, perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation; neuropathy, mono or poly [motor deficit or nerve conduction abnormality]; pulmonary infiltrates, non-fixed; sinonasal abnormality; cardiomyopathy; glomerulonephritis; alveolar hemorrhage; palpable purpura, or antineutrophil cytoplasmic antibody [ANCA] positive status); **AND**

III. Individual is on concurrent oral corticosteroid therapy (Wechsler, 2017).

Continuation requests for Nucala (mepolizumab) for **eosinophilic granulomatosis with polyangiitis** may be approved if the following criteria are met:

- I. Treatment with Nucala has resulted in clinical improvement as confirmed by the achievement of remission at some point during treatment defined as (Wechsler, 2017):
 - A. Birmingham Vasculitis Activity Score (BVAS), version 3, of 0 (on a scale from 0 to 63), and documentation is provided; **AND**
 - B. Receipt of prednisolone or prednisone at a dose of 4.0 mg or less per day.

Initial requests for Nucala (mepolizumab) for **hypereosinophilic syndrome (HES)** may be approved if the following criteria are met:

- I. Individual is 12 years of age or older; **AND**
- II. Individual has been diagnosed with hypereosinophilic syndrome (HES) for at least six months; **AND**
- III. Individual has had a trial and inadequate response to oral corticosteroids (Shomali 2019); **AND**
- IV. Documentation is provided that individual has experienced two or more HES flares within the past 12 months requiring escalation in therapy (increase in oral corticosteroid dose or increase/addition of immunosuppressive or cytotoxic therapy); **AND**
- V. Documentation is provided that individual has a blood eosinophil count greater than or equal to 1,000 cells/microliter.

Continuation requests for Nucala (mepolizumab) for **hypereosinophilic syndrome (HES)** may be approved if the following criteria are met:

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability				
Market	GA	MD	NJ	NY
Applicable	X	X	X	X

- I. Treatment with Nucala has resulted in confirmed clinically significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to decrease or absence of HES flares, improvement in fatigue).

Nucala (mepolizumab) may not be approved for the following:

- I. Individuals with non-hematologic secondary HES (including but not limited to drug hypersensitivity, parasitic helminth infection, HIV infection, non-hematologic malignancy); **OR**
- II. Individuals with FIP1L1-PDGFR α kinase-positive HES.

Cinqair (reslizumab), Fasenra (benralizumab), or Nucala (mepolizumab) may not be approved when the above criteria are not met and for all other indications.

Note:

Cinqair has a black box warning for anaphylaxis. Anaphylaxis occurred with Cinqair infusion in 0.3% of participants in placebo-controlled studies. Individuals should be observed after Cinqair administration for an appropriate period of time by a healthcare professional prepared to manage anaphylaxis that can be life-threatening. Discontinue Cinqair immediately if the patient experiences signs or symptoms of anaphylaxis.

Key References:

1. Bradding P. Asthma: eosinophil disease, mast cell disease, or both? *Allergy Asthma Clin Immunol.* 2008; (4):2:84-90.
2. Chung KF, Wenzel SE, Brozek JL, et al. International European Respiratory Society/American Thoracic Society (ERS/ATS) guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J.* 2014; 43(2):343-373.
3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 11, 2021.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
5. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020. Available from: <http://ginasthma.org/gina-reports/>. Accessed on: January 8, 2021.
6. Holguin F, Cardet JC, Chung KF, et. al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. *Eur Respir J.* 2020 Jan 2;55(1):1900588.
7. King TE. Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Last updated: July 23, 2020. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: January 11, 2021.
8. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2021; Updated periodically.
9. National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. NIH Publication Number 08-5846. Updated: August 5, 2008. Available at: <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>. Accessed: January 8, 2021.
10. [Roufosse F, Kahn JE, Rothenberg ME, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. *J Allergy Clin Immunol.* 2020; 146:1397-1405.](#)

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability				
Market	GA	MD	NJ	NY
Applicable	X	X	X	X

11. Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. *Am J Hematol*. 2019;94: 1149-1166.
12. Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. *N Engl J Med*. 2017; 376(20):1921-1932.
13. Wenzel S. Treatment of severe asthma in adolescents and adults. Last updated: July 6, 2020. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: January 9, 2021.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.